Full Breakdown
Food and Drug Administration (FDA) Advisory Panel Backs Grail’s Galleri Multi-Cancer Blood Test
By Drooid · · How we work
Core Event: Advisory Panel Vote
On September 23, 2026, the FDA’s Medical Devices Advisory Committee voted 7-2 with one abstention that the benefits of Grail Inc.’s Galleri test outweigh its risks for adults 50 and older. The panel unanimously endorsed safety, while a 6-4 split addressed effectiveness.
Background & Context
Grail submitted a Premarket Approval (PMA) application on January 29, 2026. Galleri is a laboratory-developed test that analyzes cell-free DNA methylation patterns to return a “cancer signal detected” or “no cancer signal detected” result. The test is already available by prescription at a list price of $949; FDA approval would enable Medicare and private-insurer coverage.
Data & Statistics
- PATHFINDER 2 (U.S.) – 35 % 12-month sensitivity, 99.85 % specificity; PPV 77 %, NPV 99.07 %.
- NHS-Galleri (U.K.) – 31.6 % sensitivity, 99.74 % specificity; PPV 66.2 %.
- Across both trials, Galleri identified roughly 30 % of cancers diagnosed within a year, and about two-thirds of “cancer-signal detected” results were confirmed as cancer.
- Stage-specific detection: 13.6 % (stage I), 34.4 % (stage II), 44.3 % (stage III), 60.0 % (stage IV).
- In PATHFINDER 2, 72.9 % of participants with a positive result underwent at least one invasive follow-up; adverse events were mild and occurred in 4.1 % of those evaluated.
Official Statements & Responses
- Michelle Tarver, head of the FDA’s Center for Devices and Radiological Health, called the technology “genuinely promising” but stressed it must be an addition, not a replacement, to existing screenings.
- Grail representatives argued the test offers “opportunity” for patients to detect cancers such as liver and ovarian that lack routine screening.
- The FDA briefing noted no outstanding questions on analytical performance or primary safety analyses, but asked advisers to consider whether the data support labeling Galleri as an “early detection” test.
Criticism & Opposition
- Phil Castle, director of the National Cancer Institute’s Division of Cancer Prevention, warned that premature approval could give a false sense of security and “risk harm and waste resources”.
- Dr. Victor van Berkel expressed a cautious “hopeful” yes, noting that more research is needed to confirm benefit.
- Diana Zuckerman of the National Center for Health Research cautioned that patients might delay seeking care after a negative result, which “could be deadly”.
Conflicting Reports & Gaps
- The NHS-Galleri trial failed its primary endpoint of demonstrating a statistically significant reduction in advanced-stage cancers, a shortcoming omitted from the FDA’s initial briefing but expected to be discussed by the panel.
- FDA staff found no major safety concerns, yet the panel was divided 6-4 on whether the evidence demonstrates effectiveness, reflecting uncertainty about early-stage detection capability.
Verbatim Quotes
- “It's a new era for early cancer detection, and if the FDA approves it, it validates the overall concept," says Cristian Tomasetti, director of City of Hope cancer center's early detection and monitoring division.” — Cristian Tomasetti, City of Hope
- “This increases our confidence even more on FDA approval — almost derisked,” — Subbu Nambi, Guggenheim analyst
- “Patients want opportunity, they want options,” — Dr. Mylynda Massart, University of Pittsburgh
Why It Matters
Approval would make Galleri eligible for Medicare reimbursement, potentially expanding access to a test that can detect over 50 cancer types, including those without existing screening programs. Limited early-stage detection rates and the need for follow-up procedures raise questions about overall clinical benefit and health-system costs.
What’s Next
The FDA is expected to issue a final decision in the coming months, with a formal determination anticipated by the first half of 2027.